Personalis Receives Expanded Medicare Coverage for NeXT Personal Test
Personalis (PSNL) announced expanded Medicare coverage for its NeXT Personal minimal residual disease test in the U.S., leading to a ~5% rise in premarket trading. This decision is expected to increase access and adoption of their cancer diagnostic product.
Tickers: $PSNL
Topics: biotech healthcare medical_testing